HIV Enteropathy Clinical Trial
Official title:
A Phase 3, Multicenter, Open-Label Evaluation of the Safety and Tolerability of Crofelemer in HIV-Positive Subjects With Diarrhea
This study is being conducted to evaluate the safety and tolerability of crofelemer 125 mg twice a day, taken orally, over 48 weeks of therapy in human immunodeficiency virus-positive (HIV+) subjects with diarrhea.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00816842 -
Plasma Citrulline Concentration in Tropical Enteropathy
|
N/A |